BioXcel Therapeutics, Inc., a biopharmaceutical company that harnesses the power of artificial intelligence to develop revolutionary medicines in neuroscience and immuno-oncology, has made significant strides in its drug re-innovation approach which combines big data and machine learning algorithms to identify new therapeutic indices. The Connecticut-based company's innovative product, IGALMI, is a sublingual film formulation of dexmedetomidine that treats agitation associated with bipolar I or II disorder, and schizophrenia in adults. BXCL501, aimed at treating agitation in Alzheimer's disease patients and adjunctive treatment of major depressive disorder patients, is also being rigorously tested in clinical trials. Additionally, the company is developing BXCL502 to alleviate chronic agitation in dementia and BXCL701, an orally administered systemic innate immunity activator, for advanced solid tumors resistant to checkpoint inhibitors. With its incorporation in 2017 and a robust research and development program, BioXcel Therapeutics, Inc. is steadfastly positioning themselves as a formidable player in the biopharmaceutical industry.